全球血管运动性更年期症状 (VMS) 治疗市场 – 行业趋势和 2031 年预测

血管运动性更年期症状 (VMS) 治疗市场分析和规模

血管舒缩性更年期症状 (VMS) 治疗市场的发展是由全球女性更年期症状的日益普遍所推动的。激素疗法，尤其是雌激素疗法，仍然是一种广泛使用且有效的 VMS 治疗方法，尽管对其安全性的担忧导致了对替代疗法的需求增加。非激素疗法，如选择性血清素再摄取抑制剂 (SSRI) 和血清素-去甲肾上腺素再摄取抑制剂 (SNRI)，因其疗效和安全性而越来越受欢迎。人们对更年期症状及其对生活质量的影响的认识不断提高，促使女性寻求治疗，进一步推动市场增长。

2023 年全球血管运动性更年期症状 (VMS) 治疗市场规模价值 177.5 亿美元，预计到 2031 年将达到 287.2 亿美元，2024 年至 2031 年预测期内的复合年增长率为 6.20%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分       

Market Definition

Vasomotor Menopausal Symptoms (VMS), also known as hot flashes or night sweats, are common symptoms experienced by women during menopause. These symptoms are caused by hormonal changes, specifically the decline in estrogen levels, which can impact the body's ability to regulate temperature. VMS treatment aims to alleviate these symptoms and improve the quality of life for women experiencing them. Treatment options include hormone therapy (estrogen therapy), which can effectively reduce the frequency and severity of VMS, and non-hormonal treatments such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and lifestyle changes.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics

Drivers

• Increasing Aging Population   

With women living longer, the number of women experiencing menopause and its associated symptoms, including VMS, is expected to rise. As women age, the decline in estrogen levels leads to symptoms such as hot flashes and night sweats. This demographic trend creates a growing demand for effective VMS treatment options, driving market growth.   

• Technological Advancements in Treatment Options   

Ongoing technological advancements include the development of new drug formulations and delivery methods that offer more effective and convenient treatment options for women experiencing VMS. Transdermal patches and gels, offer a non-oral method for hormone therapy, providing women with a variety of options for managing their symptoms. In addition, novel drug formulations and delivery methods aim to improve treatment efficacy and patient compliance, further boosting market growth.

Opportunities

• Rising Awareness and Treatment-seeking Behavior    

Women are becoming more informed about the impact of VMS on their quality of life and are actively seeking effective treatment options to manage these symptoms. This is supported by a growing body of information available through various channels, including healthcare providers, online resources, and community outreach programs. With growing awareness, an increasing number of women are expected to seek treatment for VMS, thereby expanding the market for VMS treatment options.

• Development of Novel Treatment Options   

The development of novel treatment options for Vasomotor Menopausal Symptoms (VMS), such as new drug formulations and non-hormonal therapies, has the potential to meet market demands by providing women experiencing VMS with more effective and safer options. For instance, new drug formulations may provide improved symptom relief with fewer side effects, while non-hormonal therapies offer alternatives for women who cannot or prefer not to use hormone-based treatments. These advancements in treatment options are likely to drive market expansion as they provide more choices for patients and healthcare providers.

Restraints/Challenges

• Safety Concerns Associated with Hormone Therapy   

Safety concerns regarding the long-term use of hormone therapy, particularly the risk of cardiovascular events and cancer, have led to a decline in the use of hormone therapy and an increased demand for alternative treatments. Healthcare providers and patients are increasingly cautious about the risks associated with hormone therapy, leading to a shift towards non-hormonal treatment options. As a result, market growth for hormone therapy products is being impacted by these safety concerns.    

• Availability of Non-pharmacological Alternatives  

The availability of non-pharmacological alternatives, such as lifestyle modifications and alternative therapies, is often preferred by women seeking natural or holistic approaches to managing VMS, as they may perceive them to be safer or more in line with their personal beliefs and values. Non-pharmacological alternatives include dietary changes, exercise, stress management techniques, and acupuncture, among others. The availability and acceptance of these alternatives by women experiencing VMS contribute to the limited growth of the pharmacological treatment market, as some women may choose these options over traditional medication.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Vasomotor menopausal symptoms (VMS) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2024, Knight Therapeutics Inc. announced the launch of Imvexxy and Bijuva in Canada. Imvexxy is indicated for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). It is the only product in its therapeutic class to offer 4 mcg and 10 mcg doses. BIJUVA is the first Health Canada-approved combination of 1 mg of estradiol and 100 mg of micronized progesterone in a single daily oral capsule. It is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus
• In May 2023, Astellas Pharma Inc.'s VEOZAH (fezolinetant) became the first nonhormonal neurokinin 3 (NK3) receptor antagonist to receive FDA approval. VEOZAH is indicated for the treatment of vasomotor symptoms (VMS) associated with menopause.      
• In March 2022, Amyris, Inc. acquired MenoLabs, LLC, a company specializing in treating menopausal symptoms and conducting research in this field. Through this acquisition, Amyris, Inc. expanded its portfolio of menopausal treatment products.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Scope

The market is segmented on the basis of drug class, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antidepressants
• Fluoxetine
• Paroxetine
• Sertraline
• Hormone Therapy
• Anticonvulsant
• Phenytoin
• Phenobarbital
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, drug class, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the market due to its advanced and comprehensive healthcare infrastructure. The region boasts well-established healthcare facilities and services, ensuring widespread access to medical automation technologies. Moreover, North America exhibits high levels of consumer awareness regarding healthcare advancements, leading to a more receptive market for medical automation solutions. The presence of key market players and ongoing technological innovations further solidify the market growth in the region.

由于患者人数不断增加、医疗保健领域的投资不断增加以及政府支持力度不断加大，预计亚太地区将在预测期内实现显著增长。传统中医在控制更年期症状和加速更年期治疗市场增长方面发挥着重要作用。由于现代治疗方法和传统日本医学（如汉方疗法）共存，女性在控制更年期症状方面拥有多种选择。这些因素加剧了日本更年期治疗的采用。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、血管运动性更年期症状 (VMS) 治疗市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和血管舒缩性更年期症状 (VMS) 治疗市场份额分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

• 浙江华海药业股份有限公司 (中国)
• Teva Pharmaceutical Industries Ltd.（以色列）
• 辉瑞公司 (美国)
• Hikma Pharmaceutical PLC（英国）
• Amneal Pharmaceuticals LLC.（美国）
• Alembic Pharmaceuticals Limited（印度）
• Zydus 集团 (印度)
• Dr. Reddy's Laboratories Ltd（印度）
• Abbvie, Inc（美国）
• 太阳制药工业有限公司 (印度)
• Apotex Inc（加拿大）
• Aurobindo Pharma（印度）
• Endo Pharmaceuticals plc（爱尔兰）
• 鲁冰花（印度）
• 诺华公司（瑞士）
• WOCKHARDT（印度）

SKU-52905